Protagonist Therapeutics has been granted a patent for a pharmaceutical composition containing peptide inhibitors of the interleukin-23 receptor (IL-23R) for treating autoimmune inflammation and related diseases. The composition includes specific peptides and excipients. GlobalData’s report on Protagonist Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Protagonist Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Protagonist Therapeutics, Cyclosporin derivatives was a key innovation area identified from patents. Protagonist Therapeutics's grant share as of April 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.

Peptide inhibitors of il-23 receptor for autoimmune inflammation

Source: United States Patent and Trademark Office (USPTO). Credit: Protagonist Therapeutics Inc

The granted patent (Publication Number: US11939361B2) discloses a pharmaceutical composition for treating inflammatory diseases. The composition includes a specific peptide (SEQ ID NO: 1) or its pharmaceutically acceptable salt or solvate form, ranging from 0.1% to 20% of the composition, along with pharmaceutically acceptable excipients. The peptide can be in an acetate form, with the option of being in an amorphous form, and the amount administered can vary from 1 mg to 1000 mg.

Furthermore, the pharmaceutical composition may also contain an absorption enhancer in addition to the peptide and excipients. The patent also outlines a method for treating inflammatory diseases in a subject by administering a therapeutically effective amount of the pharmaceutical composition. The composition's effectiveness in treating inflammatory diseases is highlighted, emphasizing the specific peptide's role in the formulation. The patent provides detailed specifications regarding the chemical structure of the peptide and the varying amounts that can be included in the composition for optimal therapeutic results.

To know more about GlobalData’s detailed insights on Protagonist Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies